Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma

European Journal of Endocrinology

Volumn 172, Issue 2, 2015, Pages 195-204

  Albarel, Frédérique ^a,b   Gaudy, Caroline ^c   Castinetti, Frédéric ^a,b   Carré, Tiphaine ^c   Morange, Isabelle ^a,b   Conte Devolx, Bernard ^a,b   Grob, Jean Jacques ^c   Brue, Thierry ^a,b  

^a TIMONE HOSPITAL   (France)

^b University of Mediterranée   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IPILIMUMAB; PLACEBO; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; ARTICLE; ASTHENIA; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOTROPH DEFICIENCY; DIARRHEA; DISEASE SEVERITY; DRUG WITHDRAWAL; ENTEROCOLITIS; FEMALE; FOLLOW UP; GONADOTROPH DEFICIENCY; HEADACHE; HEPATITIS; HORMONE DEFICIENCY; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSITIS; IMAGE ANALYSIS; KIDNEY FAILURE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; RASH; SYMPTOM; THYROTROPH DEFICIENCY; WEAKNESS; AGED; BLOOD; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PITUITARY DISEASES; RANDOMIZED CONTROLLED TRIAL; SKIN NEOPLASMS; TIME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; PITUITARY DISEASES; SKIN NEOPLASMS; TIME FACTORS;

EID: 84922584243     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0845     Document Type: Article

References (37)

1. Buxton N & Robertson I. Lymphocytic and granulocytic hypophysitis: a single centre experience. British Journal of Neurosurgery 2001 15 242-245. Discussion 245-246. (doi:10.1080/02688690120057664)
2. Laws ER, Vance ML & Jane JA Jr. Hypophysitis. Pituitary 2006 9 331-333. (doi:10.1007/s11102-006-0415-6)
3. Carmichael JD. Update on the diagnosis and management of hypophysitis. Current Opinion in Endocrinology, Diabetes, and Obesity 2012 19 314-321. (doi:10.1097/MED.0b013e32835430ed)
4. Glezer A & Bronstein MD. Pituitary autoimmune disease: nuances in clinical presentation. Endocrine 2012 42 74-79. (doi:10.1007/s12020-012-9654-7)
5. Falorni A, Minarelli V, Bartoloni E., Alunno A & Gerli R. Diagnosis and classification of autoimmune hypophysitis. Autoimmunity Reviews 2014 13 412-416. (doi:10.1016/j.autrev.2014.01.021)
6. Caturegli P, Lupi I, Landek-Salgado M, Kimura H & Rose NR. Pituitary autoimmunity: 30 years later. Autoimmunity Reviews 2008 7 631-637. (doi:10.1016/j.autrev.2008.04.016)
7. Maker AV, Attia P & Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. Journal of Immunology 2005 175 7746-7754. (doi:10.4049/jimmunol.175.11.7746)
8. Tivol EA, Borriello F, Schweitzer A.N., Lynch WP, Bluestone JA & Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995 3 541-547. (doi:10.1016/ 1074-7613(95)90125-6)
9. Chambers CA, Kuhns MS, Egen JG & Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology 2001 19 565-594. (doi:10.1146/annurev.immunol.19.1.565)
10. Hodi FS, O'Day SJ, McDermott DF, Weber R.W., Sosman JA, Haanen JB, Gonzalez R, Robert C., Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010 363 711-723. (doi:10.1056/ NEJMoa1003466)
11. Robert C, Thomas L, Bondarenko I., O'Day S, Weber J, Garbe C., Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine 2011 364 2517-2526. (doi:10.1056/NEJMoa1104621)
12. Dillard T, Yedinak CG, Alumkal J & Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010 13 29-38. (doi:10.1007/s11102-009-0193-z)
13. Weber JS, Kähler KC & Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology 2012 30 2691-2697. (doi:10.1200/JCO.2012.41.6750)
14. Maker AV, Phan GQ, Attia P, Yang J.C., Sherry RM, Topalian SL, Kammula US, Royal R.E., Haworth LR, Levy C et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Annals of Surgical Oncology 2005 12 1005-1016. (doi:10.1245/ASO.2005.03.536)
15. Phan GQ, Yang JC, Sherry R.M., Hwu P., Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth L.R., Seipp CA, Freezer LJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. PNAS 2003 100 8372-8377. (doi:10.1073/pnas.1533209100)
16. Attia P, Phan GQ, Maker A.V., Robinson MR, Quezado MM, Yang JC, Sherry R.M., Topalian SL, Kammula US, Royal RE et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology 2005 23 6043-6053. (doi:10.1200/JCO.2005.06.205)
17. O'Day S.J., Hamid O & Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007 110 2614-2627. (doi:10.1002/cncr.23086)
18. Downey SG, Klapper JA, Smith F.O., Yang JC, Sherry RM, Royal RE, Kammula U.S., Hughes MS, Allen TE, Levy CL et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clinical Cancer Research 2007 13 6681-6688. (doi:10.1158/1078-0432.CCR-07-0187)
19. Faje AT, Sullivan R, Lawrence D., Tritos NA, Fadden R, Klibanski A & Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. Journal of Clinical Endocrinology and Metabolism 2014 99 4078-4085. (doi:10.1210/jc.2014-2306)
20. Juszczak A, Gupta A, Karavitaki N., Middleton MR & Grossman AB. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. European Journal of Endocrinology 2012 167 1-5. (doi:10.1530/EJE-12-0167)
21. Yang JC, Hughes M, Kammula U., Royal R, Sherry RM, Topalian S.L., Suri KB, Levy C, Allen T, Mavroukakis S et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of Immunotherapy 2007 30 825-830. (doi:10.1097/CJI.0b013e318156e47e)
22. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J & Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. American Journal of Neuroradiology 2009 30 1751-1753. (doi:10.3174/ajnr.A1623)
23. Blansfield JA, Beck KE, Tran K, Yang J.C., Hughes MS, Kammula US, Royal RE, Topalian S.L., Haworth LR, Levy C et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. Journal of Immunotherapy 2005 28 593-598. (doi:10.1097/01.cji.0000178913.41256.06)
24. Min L, Vaidya A & Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocrine Practice 2012 18 351-355. (doi:10.4158/EP11273.OR)
25. Maker AV, Yang JC, Sherry R.M., Topalian SL, Kammula US, Royal RE, Hughes M, Yellin M.J., Haworth LR, Levy C et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. Journal of Immunotherapy 2006 29 455-463. (doi:10.1097/01.cji.0000208259.73167.58)
26. Weber JS, O'Day S, Urba W, Powderly J., Nichol G, Yellin M, Snively J & Hersh E. Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology 2008 26 5950-5956. (doi:10.1200/JCO.2008.16.1927)
27. Caturegli P, Newschaffer C, Olivi A., Pomper MG, Burger PC & Rose NR. Autoimmune hypophysitis. Endocrine Reviews 2005 26 599-614. (doi:10.1210/er.2004-0011)
28. Corsello SM, Barnabei A, Marchetti P., De Vecchis L, Salvatori R & Torino F. Endocrine side effects induced by immune checkpoint inhibitors. Journal of Clinical Endocrinology and Metabolism 2013 98 1361-1375. (doi:10.1210/jc.2012-4075)
29. Iwama S, DeRemigis A, Callahan M.K., Slovin SF, Wolchok JD & Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science Translational Medicine 2014 6 230ra45. (doi:10.1126/scitranslmed.3008002)
30. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007 12 864-872. (doi:10.1634/theoncologist.12-7-864)
31. Lammert A, Schneider HJ, Bergmann T, Benck U., Krämer BK, Gärtner R, Metzner C., Schöfl C & Berking C. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Experimental and Clinical Endocrinology & Diabetes 2013 121 581-587. (doi:10.1055/s-0033-1355337)
32. Torino F, Barnabei A, De Vecchis L, Salvatori R & Corsello SM. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 2012 17 525-535. (doi:10.1634/theoncologist.2011-0404)
33. Boasberg P, Hamid O & O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Seminars in Oncology 2010 37 440-449. (doi:10.1053/j.seminoncol.2010.09.004)
34. Van der Hiel B, Blank CU, Haanen JB & Stokkel MP. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. Clinical Nuclear Medicine 2013 38 182-184. (doi:10.1097/RLU.0b013e3182639765)
35. Torino F, Barnabei A, Paragliola R.M., Marchetti P., Salvatori R & Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. European Journal of Endocrinology 2013 169 R153-R164. (doi:10.1530/EJE-13-0434)
36. Topalian SL, Hodi FS, Brahmer J.R., Gettinger SN, Smith DC, McDermott DF, Powderly J.D., Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 2012 366 2443-2454. (doi:10.1056/ NEJMoa1200690)
37. Ricciuti A, De Remigis A, Landek-Salgado MA, De Vincentiis L, Guaraldi F, Lupi I, Iwama S, Wand GS, Salvatori R & Caturegli P. Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. Journal of Clinical Endocrinology and Metabolism 2014 99 1758-1766. (doi:10.1210/jc.2014-1049)